Archives
Archive
VIDA CEO Susan Wood Presents at the LSI Emerging Medtech Summit
VIDA CEO Susan Wood presents at the LSI Emerging Medtech Summit to explain how the lung has been underfunded because lung trials are slow and very costly which disincentives investment. VIDA’s intelligence solution blocks these barriers.
Read MoreVIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence
VIDA is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal.
Read MoreVIDA appoints digital health technology leader Karen Drexler to board of directors
Growing bench of proven leaders in clinical lung intelligence and health technology bolsters both product and commercial advances CORALVILLE, Iowa, Aug. 11, 2020 /PRNewswire/ — VIDA Diagnostics, Inc.
Read More15 Companies That Are Saving The World From Covid-19
In the wake of the Covid-19 pandemic we all can feel lost, helpless and bereft of hope at times. We turn on the news to see conflicting “experts” telling us to do opposite things for the sake of our health and the public’s health.
Read MoreVIDA’s CEO named in the Top 50 Healthcare Technology CEOs of 2020
The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2020. Now more than ever, with our global community impacted by a severe pandemic, the importance of the healthcare technology field is at the forefront.
Read MoreBlue Heron Announces Investment in VIDA
Blue Heron Capital Invests in Leading AI-Powered Lung Imaging Analysis Technology Blue Heron Capital, a Richmond, Virginia-based growth equity fund, announced today its participation in an $11 million investment round in VIDA Diagnostics, Inc.
Read More